"The Report Sarilumab
(Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Description
Sarilumab (Rheumatoid
Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Regeneron and Sanofis
sarilumab is the first fully-human mAb against IL-6, and is in Phase
III of development for RA. Sarilumab is directed against IL-6R and
reduces inflammation, thus preventing the joint damage that is common
in RA. Although Actemra is an anti-IL6 mAb currently approved for RA,
this biologic agent is a recombinant human mAb and does not offer the
same safety advantages of a fully-human mAb.
View
Full Report at http://www.marketresearchreports.biz/analysis/247155
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Sarilumab including product description, safety and efficacy profiles
as well as a SWOT analysis.
- Sales forecast for Sarilumab
for the top 8 countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, the UK, Japan and
Australia.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Sarilumab
performance.
- Obtain sales forecast for
Sarilumab from 2013-2023 in top 8 countries (the US, France, Germany,
Italy, Spain, the UK and Japan and Australia).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports
14
3 Disease Overview 15
3.1 Etiology and
Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Symptoms 20
3.3 Prognosis 21
3.4 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment
Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines 24
4.1.3 Leading Prescribed Drugs
for the Treatment of RA 34
4.1.4 Clinical Practice 35
5 Competitive Assessment 41
5.1 Overview 41
6 Unmet Need and Opportunity
43
6.1 Overview 43
6.2 Development of
Cost-Effective Therapies 44
6.2.1 Unmet Need 44
6.2.2 Gap Analysis 45
6.2.3 Opportunity 45
6.3 Biomarkers to Predict
Responsiveness to Therapy 45
6.3.1 Unmet Need 45
6.3.2 Gap Analysis 47
6.3.3 Opportunity 48
7 Overview 49
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment